8ew6: Difference between revisions
New page: '''Unreleased structure''' The entry 8ew6 is ON HOLD Authors: Kiefer, J.R., Williams, S., Davies, C.W., Koerber, J.T., Sriraman, S.K., Yin, Y.P. Description: Anti-human CD8 VHH complex... |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Anti-human CD8 VHH complex with CD8 alpha== | |||
<StructureSection load='8ew6' size='340' side='right'caption='[[8ew6]], [[Resolution|resolution]] 1.90Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[8ew6]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Lama_glama Lama glama]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8EW6 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8EW6 FirstGlance]. <br> | |||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8ew6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8ew6 OCA], [https://pdbe.org/8ew6 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8ew6 RCSB], [https://www.ebi.ac.uk/pdbsum/8ew6 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8ew6 ProSAT]</span></td></tr> | |||
</table> | |||
== Disease == | |||
[https://www.uniprot.org/uniprot/CD8A_HUMAN CD8A_HUMAN] Defects in CD8A are a cause of familial CD8 deficiency (CD8 deficiency) [MIM:[https://omim.org/entry/608957 608957]. Familial CD8 deficiency is a novel autosomal recessive immunologic defect characterized by absence of CD8+ cells, leading to recurrent bacterial infections. | |||
== Function == | |||
[https://www.uniprot.org/uniprot/CD8A_HUMAN CD8A_HUMAN] Identifies cytotoxic/suppressor T-cells that interact with MHC class I bearing targets. CD8 is thought to play a role in the process of T-cell mediated killing. CD8 alpha chains binds to class I MHC molecules alpha-3 domains. | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
PURPOSE: Cancer immunotherapies (CITs) have revolutionized the treatment of certain cancers, but many patients fail to respond or relapse from current therapies, prompting the need for new CIT agents. CD8(+) T cells play a central role in the activity of many CITs, and thus, the rapid imaging of CD8(+) cells could provide a critical biomarker for new CIT agents. However, existing (89)Zr-labeled CD8 PET imaging reagents exhibit a long circulatory half-life and high radiation burden that limit potential applications such as same-day and longitudinal imaging. METHODS: To this end, we discovered and developed a 13-kDa single-domain antibody (VHH5v2) against human CD8 to enable high-quality, same-day imaging with a reduced radiation burden. To enable sensitive and rapid imaging, we employed a site-specific conjugation strategy to introduce an (18)F radiolabel to the VHH. RESULTS: The anti-CD8 VHH, VHH5v2, demonstrated binding to a membrane distal epitope of human CD8 with a binding affinity (K(D)) of 500 pM. Subsequent imaging experiments in several xenografts that express varying levels of CD8 demonstrated rapid tumor uptake and fast clearance from the blood. High-quality images were obtained within 1 h post-injection and could quantitatively differentiate the tumor models based on CD8 expression level. CONCLUSION: Our work reveals the potential of this anti-human CD8 VHH [(18)F]F-VHH5v2 to enable rapid and specific imaging of CD8(+) cells in the clinic. | |||
Development of an (18)F-labeled anti-human CD8 VHH for same-day immunoPET imaging.,Sriraman SK, Davies CW, Gill H, Kiefer JR, Yin J, Ogasawara A, Urrutia A, Javinal V, Lin Z, Seshasayee D, Abraham R, Haas P, Koth C, Marik J, Koerber JT, Williams SP Eur J Nucl Med Mol Imaging. 2022 Nov 8. doi: 10.1007/s00259-022-05998-0. PMID:36346438<ref>PMID:36346438</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: | <div class="pdbe-citations 8ew6" style="background-color:#fffaf0;"></div> | ||
[[Category: | == References == | ||
[[Category: | <references/> | ||
[[Category: | __TOC__ | ||
[[Category: | </StructureSection> | ||
[[Category: Sriraman | [[Category: Homo sapiens]] | ||
[[Category: Lama glama]] | |||
[[Category: Large Structures]] | |||
[[Category: Davies CW]] | |||
[[Category: Kiefer JR]] | |||
[[Category: Koerber JT]] | |||
[[Category: Sriraman SK]] | |||
[[Category: Williams S]] | |||
[[Category: Yin YP]] | |||
Latest revision as of 13:16, 24 November 2022
Anti-human CD8 VHH complex with CD8 alphaAnti-human CD8 VHH complex with CD8 alpha
Structural highlights
DiseaseCD8A_HUMAN Defects in CD8A are a cause of familial CD8 deficiency (CD8 deficiency) [MIM:608957. Familial CD8 deficiency is a novel autosomal recessive immunologic defect characterized by absence of CD8+ cells, leading to recurrent bacterial infections. FunctionCD8A_HUMAN Identifies cytotoxic/suppressor T-cells that interact with MHC class I bearing targets. CD8 is thought to play a role in the process of T-cell mediated killing. CD8 alpha chains binds to class I MHC molecules alpha-3 domains. Publication Abstract from PubMedPURPOSE: Cancer immunotherapies (CITs) have revolutionized the treatment of certain cancers, but many patients fail to respond or relapse from current therapies, prompting the need for new CIT agents. CD8(+) T cells play a central role in the activity of many CITs, and thus, the rapid imaging of CD8(+) cells could provide a critical biomarker for new CIT agents. However, existing (89)Zr-labeled CD8 PET imaging reagents exhibit a long circulatory half-life and high radiation burden that limit potential applications such as same-day and longitudinal imaging. METHODS: To this end, we discovered and developed a 13-kDa single-domain antibody (VHH5v2) against human CD8 to enable high-quality, same-day imaging with a reduced radiation burden. To enable sensitive and rapid imaging, we employed a site-specific conjugation strategy to introduce an (18)F radiolabel to the VHH. RESULTS: The anti-CD8 VHH, VHH5v2, demonstrated binding to a membrane distal epitope of human CD8 with a binding affinity (K(D)) of 500 pM. Subsequent imaging experiments in several xenografts that express varying levels of CD8 demonstrated rapid tumor uptake and fast clearance from the blood. High-quality images were obtained within 1 h post-injection and could quantitatively differentiate the tumor models based on CD8 expression level. CONCLUSION: Our work reveals the potential of this anti-human CD8 VHH [(18)F]F-VHH5v2 to enable rapid and specific imaging of CD8(+) cells in the clinic. Development of an (18)F-labeled anti-human CD8 VHH for same-day immunoPET imaging.,Sriraman SK, Davies CW, Gill H, Kiefer JR, Yin J, Ogasawara A, Urrutia A, Javinal V, Lin Z, Seshasayee D, Abraham R, Haas P, Koth C, Marik J, Koerber JT, Williams SP Eur J Nucl Med Mol Imaging. 2022 Nov 8. doi: 10.1007/s00259-022-05998-0. PMID:36346438[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||